PRPresley Roberts

Presley Roberts

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Presley Roberts has a total of 23 co-authors. Here are the top co-authors by number of shared publications:

  • Andreas Vogt

    Department of Computational & Systems Biology, Organ Pathobiology and Therapeutics Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA 15260, USA

    2 shared publications
  • Arthur Sorlin

    National Center of Genetics, Laboratoire National de Santé, L-3555 Dudelange, Luxembourg

    2 shared publications
  • Eduard Johannes van Beers

    Center for Benign Hematology, Thrombosis and Hemostasis—Van Creveldkliniek University Medical Center Utrecht, Utrecht University Utrecht The Netherlands

    2 shared publications
  • Emmanuel Scalais

    Pediatric Neurology Unit, Department of Pediatrics, Centre Hospitalier de Luxembourg, L-1210 Luxembourg, Luxembourg

    2 shared publications
  • Gregg E. Homanics

    Department of Anesthesiology & Perioperative Medicine, University of Pittsburgh, Pittsburgh, PA, USA; Department of Neurobiology, University of Pittsburgh, Pittsburgh, PA, USA; Department of Pharmacology & Chemical Biology, University of Pittsburgh, Pittsburgh, PA, USA

    2 shared publications
  • Joseph R. Figura

    Department of Pharmacology & Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15260, USA

    2 shared publications

Latest Publications

  • Open Access

    PHD Inhibitor Vadadustat: The First Drug Therapy for Triosephosphate Isomerase Deficiency

    by Emmanuel Scalais, Priyal Patel, Sidney Satterfield, Mylène Donge, Raphael Laschiazza, Arthur Sorlin, Presley Roberts, Joseph R. Figura, Ella R. Donahue, Cindy Cui, et al.

    Background/Objectives: Triosephosphate isomerase deficiency (TPI Df) is an ultra-rare autosomal recessive glycolytic disorder characterized by symptoms of hemolytic anemia, progressive neuromuscular dysfunction, and early mortality. The TPI1E105D mutation (TPI1 variant p.Glu105Asp) accounts for most cases, though TPI Df can also arise from other pathogenic variants, including compound heterozygous TPI1 variants such as TPI1R5G/f.s (p.(Arg5Gly)/p.(Ile151Serfs*3)). TPI1R5G/f.s presents with an atypical predominantly neurological phenotype characterized by severe dystonia, dysarthria, basal ganglia involvement, and cognitive impairment, without hemolytic anemia or peripheral neuromuscular disease. Regardless of the causative allele(s), reduced mutant TPI protein stability is the central pathogenic mechanism. We previously hypothesized that pharmacological inhibition of prolyl hydroxylase domain (PHD) enzymes, leading to hypoxia-inducible factor (HIF) stabilization, could increase TPI protein levels and attenuate disease severity. Methods: We evaluated PHD inhibitors, including vadadustat and roxadustat, in patient-derived TPI1E105D/E105D fibroblasts and Tpi1E105D/E105D mouse models. In addition, vadadustat was administered off-label as compassionate therapy to a TPI Df patient. Studies assessed TPI protein levels, enzymatic activity, hematological parameters, and clinical outcomes. Results: In FB303 patient fibroblasts, vadadustat (100 μM) and roxadustat (100 μM) increased TPI protein levels by ~45% and ~68%, and TPI enzymatic activity by ~191% and ~258%, respectively. In Tpi1E105D/E105D mice, vadadustat significantly increased TPI levels in liver, kidney, and muscle tissues along with partial improvement in neuromuscular function, as assessed by rotarod performance. Supported by these findings, compassionate off-label administration with vadadustat/Vafseo was initiated in a single TPI1R5G/f.s. patient. Treatment was associated with a progressive increase in residual TPI enzymatic activity, clinical stabilization, and meaningful neurological improvement, predominantly affecting left-sided motor function, including improved upper-limb dexterity, recovery of functional grasping, and complete resolution of myoclonic-like movements. Conclusions: This report provides the first in vivo evidence that pharmacological stabilization of mutant TPI1 protein may represent a novel therapeutic strategy for TPI deficiency. Furthermore, the findings establish PHD inhibitors, such as vadadustat, as excellent candidates for disease-modifying therapy of TPI Df warranting further development and clinical investigation.

  • Open Access

    Newly Identified TPI Deficiency Treatments Function for Novel Disease-Causing Allele, TPI1R5G

    by Joseph R. Figura, Presley Roberts, Riley Sawka, Maci Chambers, Marcelo Claudio, Laura L. Vollmer, Andreas Vogt, Gregg E. Homanics, Eduard van Beers, Mylene Donge, et al.

    Background/Objectives: Triosephosphate Isomerase (TPI) is a glycolytic enzyme known to be associated with TPI deficiency, a severe form of childhood-onset glycolytic enzymopathy associated with hemolytic anemia, neuromuscular impairment and early death. Most often the disease results from the common TPI1E105D mutation, which can be either homozygous or compound heterozygous with another allele. Methods: We purified TPIR5G protein, studied mutant protein biochemistry, established and characterized TPIR5G/f.s.patient cells, and investigated newly identified compounds for their efficacy in vitro using Western blot and TPI activity assays. Results: We identified novel TPI1 alleles that result in TPI Deficiency with an atypical presentation lacking anemia and with more slowly developing neurologic and locomotor impairment. The patient was found to be compound heterozygous with a missense mutation resulting in an R5G amino acid substitution and a frameshift mutation that is a predicted null allele. To better understand disease pathogenesis in this patient, we expressed and purified the TPIR5G human protein and studied it biochemically in addition to studying TPIR5G/f.s.patient cells. We discovered that purified TPIR5G protein has wildtype activity with modestly increased dimer stability. We also discovered that steady-state TPI protein levels were markedly reduced, suggesting that the instability of the mutant protein underlies disease pathogenesis. We tested compounds recently identified in a screen for novel TPI Df therapies for their efficacy in TPIR5G/f.s.patient cells. All three compounds significantly increased TPI protein levels in patient cells. As expected, since the mutant protein retains essentially wild type activity, the increase in TPI protein levels also resulted in a significant increase in TPI activity. Conclusions: These results establish TPIR5G as a TPI Df allele, demonstrate that reduced stability of the mutant protein underlies pathogenesis akin to other disease-causing alleles, and suggest that recently discovered developing therapies will likely function broadly and should be developed as potential TPI Df therapies.